Literature DB >> 3060249

Cytogenetics of T-cell malignant lymphoma. Report of 17 cases and review of the chromosomal breakpoints.

R Berger1, L Baranger, A Bernheim, F Valensi, G Flandrin, A Berheimm.   

Abstract

Cytogenetic studies are reported on 17 T-cell malignant lymphomas (ML) including six cutaneous T-cell malignant lymphomas (CTCL). Due to the low incidence of rearrangements on bands where the T-cell receptor genes are located, other cases reported in the literature were analyzed in order to estimate the most frequent chromosomal breakpoints in ML, CTCL, and adult T-cell leukemia-lymphoma. Besides chromosomes 1 and 6q, 14q11, 7p15p21, and 7q32q35, the most frequent rearrangements involved bands 14q32, 2p11-p14, 2p23-p25, 17cen, 9p21p23, and 10p13p15. These results show that molecular studies must be concentrated on these chromosomal regions in order to identify the DNA sequences that may be involved in T-cell malignancies.

Entities:  

Mesh:

Year:  1988        PMID: 3060249     DOI: 10.1016/0165-4608(88)90082-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  BMI-1 is highly expressed in M0-subtype acute myeloid leukemia.

Authors:  Masashi Sawa; Kazuhito Yamamoto; Toshiya Yokozawa; Hitoshi Kiyoi; Asahi Hishida; Tomohiro Kajiguchi; Masao Seto; Akio Kohno; Kunio Kitamura; Yoshie Itoh; Norio Asou; Nobuyuki Hamajima; Nobuhiko Emi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

2.  Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity.

Authors:  K J Cohen; J S Hanna; J E Prescott; C V Dang
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

3.  Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.

Authors:  Hong-Xia Peng; Xiao-Dan Liu; Zi-Yan Luo; Xiao-Hong Zhang; Xue-Qun Luo; Xiao Chen; Hua Jiang; Ling Xu
Journal:  BMC Cancer       Date:  2017-01-25       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.